Head to Head Contrast: Astria Therapeutics (NASDAQ:ATXS) versus Repare Therapeutics (NASDAQ:RPTX)

Repare Therapeutics (NASDAQ:RPTX) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Repare Therapeutics and Astria Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repare Therapeutics	0	0	4	0	3.00
Astria Therapeutics	0	0	4	0	3.00

Repare Therapeutics currently has a consensus price target of $17.33, indicating a potential upside of 441.67%. Astria Therapeutics has a consensus price target of $21.25, indicating a potential upside of 136.11%. Given Repare Therapeutics’ higher probable upside, analysts clearly believe Repare Therapeutics is more favorable than Astria Therapeutics.

Insider & Institutional Ownership

85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 28.5% of Repare Therapeutics shares are held by company insiders. Comparatively, 3.4% of Astria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Repare Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Profitability

This table compares Repare Therapeutics and Astria Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repare Therapeutics	-183.43%	-39.82%	-31.84%
Astria Therapeutics	N/A	-63.65%	-33.37%

Earnings & Valuation

This table compares Repare Therapeutics and Astria Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repare Therapeutics	$51.13 million	2.32	-$93.80 million	($2.23)	-1.43
Astria Therapeutics	N/A	N/A	-$72.89 million	($2.34)	-3.85

Astria Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Repare Therapeutics beats Astria Therapeutics on 7 of the 11 factors compared between the two stocks.

About Repare Therapeutics

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

About Astria Therapeutics

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.